Ovarian Cancer

Travis Sims, MD, MPH, discusses the impact of homologous recombination deficiency status of clinical and survival outcomes in patients with advanced-stage ovarian cancer.

In an interview with Targeted Oncology, Rachel N. Grisham, MD, discussed binimetinib’s effect on patients with ovarian cancer harboring a KRAS mutation. 

David M. O’Malley, MD, discusses the prognosis and historical treatment options for patients with platinum-agnostic ovarian cancer.

In an interview with Targeted Oncology, Kathleen Moore, MD, discusses the effects of niraparib for ovarian cancer in the earlier-line setting in more detail and how she anticipates it will change clinical practice. 

In an interview with Targeted Oncology, held during the 2021 ASCO Annual Meeting, Travis Sims, MD, MPH, discussed the treatment of HRD-positive ovarian cancer and the retrospective analysis of HRD status and its impact of survival outcomes for this patient population.

David M. O’Malley, MD, discusses final analysis data from the phase 1b FORWARD II trial of mirvetuximab soravtansine plus bevacizumab as treatment of patients with platinum-agnostic ovarian cancer.

Kathleen Moore, MD, discusses the safety and efficacy profile of niraparib, based on data from the phase 3 trials, PRIMA; ENGOT-OV16/NOVA, and NORA.

Data from the phase 3 AGO-OVAR 17/BOOST/GINECO OV118/ENGOT Ov-15 trial of patients with primary epithelial ovarian, fallopian tube, or peritoneal cancer show that even though prolonged treatment with bevacizumab is feasible and safe, it does not improve survival.

Results from the final analysis of the phase 1b FORWARD II trail, show that mirvetuximab soravtansine combined with bevacizumab yielded durable responses in patients with recurrent, platinum agnostic ovarian cancer, a population with an unmet need for more effective, non-platinum treatments.

Niraparib has an acceptable safety profile for patients with platinum-sensitive recurrent ovarian cancer, regardless of the dose being adjusted for weight, according to updated results from the phase 3 NORMA trial.

In patients with ovarian cancer and BRCA mutations who were enrolled in 3 different trials, maintenance treatment with niraparib improved progression-free survival compared with placebo with no new safety signals.

Ursula A. Matulonis, MD, the chief of the Division of Gynecologic Oncology at the Dana-Farber Cancer Institute, explains how the treatment paradigm of ovarian cancer has evolved with abundance of PARP inhibitors.

The FDA has granted breakthrough therapy designation to the combination of VS-6766 and defactinib for the treatment of all patients with recurrent low-grade serous ovarian cancer.

The ovarian cancer treatment landscape, including the use of cytotoxic and targeted therapies, is continuously evolving for patients. Recent trials have evaluated PARP inhibitors, antiangiogenic agents, and other targeted therapies, and investigators are looking at strategies to individualize care for patients with ovarian cancer.

A phase 3 study showed that patients with platinum-sensitive recurrent ovarian cancer experienced improved progression-free survival on chemotherapy plus bevacizumab continued beyond disease progression.

Melissa Hardesty, MD, discusses the modern disease management of patients with ovarian cancer in the community setting.

Melissa, K. Frey, MD, the study of adequate collection of family cancer history in ovarian and other gynecological cancers in order to determine cancer risk and early interventions.

In an interview with Targeted Oncology, William H. Bradley, MD, discussed the results of the SOLO-1 trial of olaparib as a maintenance therapy for patients with ovarian cancer with a BRCA1/2 mutation, and other developments in the ovarian cancer field.

In an interview with Targeted Oncology, Ursula A. Matulonis, MD, discusses results from further follow-up of patients with ovarian cancer treated in the ENGOT-OV16/NOVA.

A leader in gynecologic oncology, Chirag Shah, MD, MPH, provides insight into the future of ovarian cancer by discussing the potential for immunotherapy, TP53 inhibition, and novel therapeutics on the horizon.

Chirag Shah, MD, MPH, discusses platinum sensitivity vs resistance impact treatment selection in subsequent lines of therapy.

An expert in gynecologic oncology reviews the PRIMA and NOVA clinical trials and discusses their implications for the management of ovarian cancer.

Chirag Shah, MD, MPH, provides key insights into factors to consider when counseling patients with ovarian cancer on the available treatment options for maintenance therapy.

Key opinion leader in obstetrics and gynecology Chirag Shah, MD, MPH, discusses best practices for molecular testing and genetic counseling for patients with newly diagnosed or relapsed ovarian cancer.

Chirag Shah, MD, MPH shares insight into factors influencing the prognosis of patients with ovarian cancer.

Chirag Shah, MD, MPH, an expert in gynecologic oncology, provides an overview of the case of a 67-year-old woman with ovarian cancer by reviewing the patient’s initial presentation, clinical work-up, and treatment.

Chirag Shah, MD, MPH, an expert in gynecologic oncology, reviews the case of a 67-year-old woman with ovarian cancer and discusses factors to consider when selecting therapy including the recent results of the PRIMA and NOVA trials of niraparib in patients with ovarian cancer.

William H. Bradley, MD discusses the 5-year follow-up of the ongoing SOLO-1 trial, which is determining the efficacy of maintenance olaparib in patients with BRCA1/2-mutated advanced ovarian cancer.

In an interview with Targeted Oncology, Katelyn Handley, MD, discussed two studies on ovarian cancer subtypes and the use of a frailty index to determine patient outcomes before, during, and after ovarian cancer debulking surgery.

In phase 1b trial, treatment with tislelizumab in combination with sitravatinib achieved early antitumor activity and demonstrated a manageable safety profile in patients with recurrent platinum-resistant epithelial ovarian cancer and were naïve to PD-1/PD-L1 inhibition.